JP2007500243A - 成長ホルモンの増進された経粘膜送達のための組成物および方法 - Google Patents

成長ホルモンの増進された経粘膜送達のための組成物および方法 Download PDF

Info

Publication number
JP2007500243A
JP2007500243A JP2006533559A JP2006533559A JP2007500243A JP 2007500243 A JP2007500243 A JP 2007500243A JP 2006533559 A JP2006533559 A JP 2006533559A JP 2006533559 A JP2006533559 A JP 2006533559A JP 2007500243 A JP2007500243 A JP 2007500243A
Authority
JP
Japan
Prior art keywords
growth hormone
subject
delivery
plasma
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006533559A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007500243A5 (https=
Inventor
キー，スティーブン・シー
デ・マイレレス，ヨルゲ・シー
グプタ，マリーニ
ヴァンガラ，シャム
Original Assignee
ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド filed Critical ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド
Publication of JP2007500243A publication Critical patent/JP2007500243A/ja
Publication of JP2007500243A5 publication Critical patent/JP2007500243A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006533559A 2003-06-09 2004-06-01 成長ホルモンの増進された経粘膜送達のための組成物および方法 Withdrawn JP2007500243A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47740303P 2003-06-09 2003-06-09
PCT/US2004/017632 WO2005004895A2 (en) 2003-06-09 2004-06-01 Compositions and methods for enhanced mucosal delivery of growth hormone

Publications (2)

Publication Number Publication Date
JP2007500243A true JP2007500243A (ja) 2007-01-11
JP2007500243A5 JP2007500243A5 (https=) 2007-07-26

Family

ID=34061913

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533559A Withdrawn JP2007500243A (ja) 2003-06-09 2004-06-01 成長ホルモンの増進された経粘膜送達のための組成物および方法

Country Status (6)

Country Link
US (1) US20050031549A1 (https=)
EP (1) EP1643970A2 (https=)
JP (1) JP2007500243A (https=)
CA (1) CA2528465A1 (https=)
MX (1) MXPA05013340A (https=)
WO (1) WO2005004895A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11918570B2 (en) 2020-04-13 2024-03-05 The Research Foundation For The State University Of New York Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
US7404489B1 (en) 2003-03-04 2008-07-29 Qol Medical, Llc Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
US20050129679A1 (en) 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
WO2006110887A2 (en) * 2005-04-11 2006-10-19 Amylin Pharmaceuticals, Inc Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
EP1899462B1 (en) * 2005-07-02 2011-03-09 Arecor Limited Stable aqueous systems comprising proteins
CU23317A1 (es) * 2005-07-22 2008-10-22 Ct De Investigacia N Y Desarro Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
JP2009504767A (ja) 2005-08-17 2009-02-05 フレミング・アンド・カンパニー・ファーマシューティカルズ ビタミンｂ１２鼻用スプレーおよび使用方法
GB0604319D0 (en) * 2006-03-03 2006-04-12 Optinose As Nasal delivery
US7998927B2 (en) * 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) * 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) * 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
WO2008006019A2 (en) * 2006-07-06 2008-01-10 Advisys Inc. Growth hormone releasing hormone treatment to decrease cholesterol levels
EP2952522B1 (en) 2007-01-31 2019-10-30 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
EP2178547A4 (en) * 2007-07-11 2011-02-16 Aerovance Inc PHARMACEUTICAL POLYPEPTIDE DRY POWDER AEROSOL FORMULATION AND MANUFACTURING METHOD
WO2009133408A2 (en) * 2008-05-01 2009-11-05 Arecor Limited Protein formulation
EP2341940A1 (en) * 2008-07-16 2011-07-13 Arecor Limited The stabilisation of proteins
EP2328607A1 (en) * 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
JP6002385B2 (ja) * 2008-09-12 2016-10-05 クリティカル ファーマシューティカルズ リミテッドＣｒｉｔｉｃａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｉｍｉｔｅｄ 医薬組成物、医薬組成物における吸収促進剤の使用方法、及び医薬組成物の製造方法
WO2010080406A1 (en) * 2008-12-18 2010-07-15 Adrem Biotech, Inc. Method for treating rhinitis and sinusitis by rhamnolipids
US8592381B2 (en) 2008-12-18 2013-11-26 Rhamnopharma Inc. Method for treating rhinitis and sinusitis by rhamnolipids
WO2011065600A1 (en) * 2009-11-25 2011-06-03 Gcbio Corp. Use of inhalable powder formulation comprising growth hormone for preventing or treating nmda receptor hypofunction-related diseases
EP2356998A1 (en) * 2010-02-17 2011-08-17 Université de Liège A pharmaceutical composition for treatment of thrombosis-related diseases comprising a fragment of prolactin (PRL)-growth hormone (GH) - placental lactogen (PL)-family protein
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
KR20170058446A (ko) 2010-08-13 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
MX2013013098A (es) * 2011-05-10 2013-12-16 Nestec Sa Metodos y composiciones para fomentar el crecimiento de la masa corporal magra.
JP2014513688A (ja) * 2011-05-10 2014-06-05 ネステク ソシエテ アノニム 減量中に除脂肪量を保持するための方法及び組成物
EP2739287B1 (en) * 2011-08-04 2017-07-05 Flexion Therapeutics, Inc. Corticosteroids for the treatment of joint pain
AR088392A1 (es) 2011-10-18 2014-05-28 Aileron Therapeutics Inc Macrociclos peptidomimeticos
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CA2862038C (en) 2012-02-15 2021-05-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
JP5797227B2 (ja) * 2013-05-21 2015-10-21 パル ファーマシューティカル， インコーポレーテッド 鼻内送達用シアノコバラミン低粘度水性製剤
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
JP6097787B2 (ja) * 2015-06-09 2017-03-15 パル ファーマシューティカル， インコーポレーテッド 鼻内送達用シアノコバラミン低粘度水性製剤
WO2018020386A1 (en) * 2016-07-27 2018-02-01 Sun Pharmaceutical Industries Limited Topical spray system of halobetasol
CA3070711C (en) 2017-07-27 2023-09-19 Locus Ip Company, Llc Compositions for enhancing bioavailability of pharmaceuticals, supplements and ingested substances
WO2019133313A1 (en) 2017-12-28 2019-07-04 Locus Ip Company, Llc Oral health composition comprising purified biosurfactants and/or their derivatives
WO2020019033A1 (en) * 2018-07-25 2020-01-30 Palmer Raymond Denis Container for amylase inhibitor delivery
CR20210618A (es) 2019-05-10 2022-03-11 Locus Ip Co Llc Composiciones y métodos para el tratamiento de las condiciones pulmonares relacionadas con biopelículas
WO2023150267A1 (en) * 2022-02-03 2023-08-10 Maison Amori Oqvpo Llc Methods, compositions and uses for treating cancer by providing medications that induce targeted tumor cell mitosis before providing chemotherapy or radiation and kits therefor
US20240299501A1 (en) * 2023-03-06 2024-09-12 Xygenyx Inc. Composition and methods of treatment using transdermal hormone supplementation
CN121648113A (zh) * 2026-02-06 2026-03-13 华中科技大学同济医学院附属同济医院 维生素b7在制备治疗变应性鼻炎的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8712176D0 (en) * 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system
US5122804A (en) * 1987-11-30 1992-06-16 Radar Data Systems, Inc. Method and apparatus for ground radar information display system
DK49791D0 (da) * 1991-03-20 1991-03-20 Novo Nordisk As Nasalt pulverpraeparat
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US20020132803A1 (en) * 2001-01-05 2002-09-19 Mahendra Dedhiya Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11918570B2 (en) 2020-04-13 2024-03-05 The Research Foundation For The State University Of New York Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition

Also Published As

Publication number Publication date
WO2005004895A2 (en) 2005-01-20
CA2528465A1 (en) 2005-01-20
WO2005004895A3 (en) 2005-09-15
MXPA05013340A (es) 2006-03-09
EP1643970A2 (en) 2006-04-12
US20050031549A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
JP2007500243A (ja) 成長ホルモンの増進された経粘膜送達のための組成物および方法
US7166575B2 (en) Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US7435720B2 (en) Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US7186691B2 (en) Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US20040258663A1 (en) Compositions and methods for enhanced mucosal delivery of interferon alpha
EP1951198B1 (en) Intranasal administration of rapid acting insulin
US7229966B2 (en) Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7186692B2 (en) Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US20100166811A1 (en) Gras composition for intranasal delivery of parathyroid hormone
US20060074025A1 (en) Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US20060069021A1 (en) Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
US20060127320A1 (en) Method of delivering parathyroid hormone to a human
US20060052305A1 (en) Method of treating osteoporosis using intranasal parathyroid hormone
US20080051332A1 (en) Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20070173447A1 (en) Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070525

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20081210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081211